Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response.
about
Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O6-methylguanine DNA methyltransferase as a biomarker for response.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Combination therapy with capec ...... e as a biomarker for response.
@en
Combination therapy with capec ...... e as a biomarker for response.
@nl
type
label
Combination therapy with capec ...... e as a biomarker for response.
@en
Combination therapy with capec ...... e as a biomarker for response.
@nl
prefLabel
Combination therapy with capec ...... e as a biomarker for response.
@en
Combination therapy with capec ...... e as a biomarker for response.
@nl
P2093
P2860
P356
P1433
P1476
Combination therapy with capec ...... e as a biomarker for response.
@en
P2093
Andrew J Alexander
Bhavana Konda
Carl R Schmidt
Jennifer A Sipos
Jessica A Hemminger
Lawrence S Kirschner
Manisha H Shah
Mary E Dillhoff
Sherif R Z Abdel-Misih
P2860
P304
104046-104056
P356
10.18632/ONCOTARGET.22001
P407
P50
P577
2017-10-24T00:00:00Z